Uncategorized-EN

  Trial name: IAG933 in Advanced Solid Tumors incl. EHE Agents: IAG933 Phase I Status Active,but not recruiting Sponsor Novartis Pharmaceuticals   This is a phase I, open-label, multi-center study of IAG933 to assesss the safety and tolerability as well as anti-tumor activity in certain patient populations. This includes patients with epithelioid hemangioendothelioma (EHE). Further…

  Trial name: ADC AVA6000 in Advanced Solid Tumors Agents: AVA6000 Phase I Status Recruiting Sponsor Avacta Life Sciences Ltd   This phase I study evaluates the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000 in patients with locally advanced and/or metastatic solid tumours incl. soft tissue sarcomas. Further information can be found on…

  Trial name: Anti-GD2 ADC M3554 in Advanced Solid Tumors Agents: M3554 Phase I Status Recruiting Sponsor EMD Serono Research & Development Institute, Inc.   This Phase I trial is testing the safety, dosage, and effectiveness of a new targeted therapy, M3554, for people with advanced cancers incl. soft tissue sarcomas. Further information can be…

  Trial name: EMERGE 101: Lurbinectedin in Ewing’s Sarcoma Agents: Lurbinectedin Phase I/II Status Recruiting Sponsor Jazz Pharmaceuticals   This phase I/II study evaluates the safety, efficacy, and optimal dosing of lurbinectedin in pediatric and young adult patients with previously treated recurrent or refractory Ewing sarcoma. Further information can be found on clinicaltrials.gov.   WHO…

First-in-human trial of DS-2243a in participants with advanced solid tumors Agents: DS-2243a Phase I Status Open, recruiting Sponsor Daiichi Sankyo   Further information: https://clinicaltrials.gov/study/NCT06644755   This study evaluates safety, tolerability, and efficacy of DS-2243a as a treatment for participants with advanced solid tumors incl. synovial sarcoma and myxoid/round cell liposarcoma.   WHO is the trial…

Treatment of Emactuzumab in Tenosynovial Giant Cell Tumors (TANGENT) Agents: Emactuzumab Phase III Status Active, but not recruiting Sponsor SynOx Therapeutics   For further information please also consult ClinicalTrials.gov.   This is a multicenter, phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of emactuzumab for the treatment of patients…

  Trial name: INBRX-109 in Ewing sarcomas and SDH-deficient GIST Agents: INBRX-109 in combination with different therapies Phase I Status Recruiting Sponsor Inhibrx, Inc. This is a first-in-human, open-label, non-randomized phase 1 trial of INBRX-109 for patients with locally advanced or metastatic solid tumors including certain subtypes of sarcomas and GIST. Further information can be…